Call to Schedule Free Consultation at Over 80 Centers Worldwide!
Autoimmune
Cardiovascular
Endocrine
Gastrointestinal
Liver
Musculoskeletal
Neurological
Other
Respiratory/Pulmonary
Reproductive
Renal/Kidney
Urologic
Autoimmune
Cardiovascular
Endocrine
Gastrointestinal
Liver
Musculoskeletal
Neurological
Other
Respiratory/Pulmonary
Reproductive
Renal/Kidney
Urologic
Written by Dr. David Greene, MD, PhD, MBA on May 6, 2026
For millions of people living with knee osteoarthritis, finding durable, effective pain relief without surgery is a constant challenge. Hyaluronic acid (HA) injections—sometimes called “rooster comb” injections or viscosupplementation—have been a go-to non-surgical option for decades. But for many patients, their effectiveness diminishes over time. An important question has emerged in orthopedic and regenerative medicine circles: Can mesenchymal stem cell therapy offer a better alternative?
A growing body of evidence suggests the answer may be yes. Recent comparative research points to stem cell therapy for knee arthritis as a meaningfully superior option for patients who have plateaued on conventional injectable treatments.
Hyaluronic acid is a naturally occurring substance found in joint fluid that provides cushioning and lubrication. In patients with knee osteoarthritis, this fluid degrades in quality and quantity, contributing to pain and stiffness.
HA injections—marketed under brand names such as Synvisc, Euflexxa, and Orthovisc—are injected directly into the knee joint to temporarily restore lubrication. The treatment has been widely used since the 1990s. For a deeper look at how this compares with biologic alternatives, see R3’s overview of the top benefits of hyaluronic acid and where its limitations begin.
While HA injections can provide meaningful short-term relief for some patients, clinical outcomes are variable. Major limitations include:
Diminishing returns over time: Many patients report that repeated courses of HA therapy become progressively less effective.
Moderate effect sizes: Meta-analyses of HA trials have shown modest benefits that may not be clinically significant for all patients.
No disease-modifying effect: HA does not slow cartilage degradation; it primarily manages symptoms.
For patients whose response to HA has plateaued, understanding what makes regenerative medicine different from other forms of treatment becomes an important next step.
Mesenchymal stem cells (MSCs) are multipotent adult stem cells found in bone marrow, adipose (fat) tissue, and other sources including umbilical cord-derived tissue. Unlike embryonic stem cells, MSCs do not raise the same ethical concerns and are widely used in clinical research.
In the context of joint disease, MSCs are of particular interest because they:
Have demonstrated the ability to differentiate into cartilage-producing cells (chondrocytes) under the right conditions
Secretes anti-inflammatory cytokines that may reduce joint inflammation
Release growth factors that support tissue repair and regeneration
May modulate the immune environment within an arthritic joint
Understanding how stem cell therapy works at a biological level can help patients set realistic expectations before pursuing treatment. It is important to note that MSC therapy for knee osteoarthritis is still considered an investigational treatment in many regulatory contexts, though it is legally offered at licensed regenerative medicine clinics in the United States.
A systematic review and meta-analysis published in the peer-reviewed journal Arthroscopy: The Journal of Arthroscopic & Related Surgery examined the comparative outcomes of MSC injections versus HA injections in patients with knee osteoarthritis. The analysis pooled data from more than 10 individual studies involving over 800 patients.
This type of study—aggregating data across multiple controlled trials—carries significant weight in evidence-based medicine because it reduces the impact of any single study’s limitations or biases. You can explore what the latest research findings say about stem cell therapy benefits for knee arthritis for additional context on the evolving evidence base.
The meta-analysis found that mesenchymal stem cell injections outperformed hyaluronic acid injections across two critical outcome measures:
Outcome | Time Point | Favored Treatment |
Pain relief | 6 months | Mesenchymal stem cells |
Functional improvement | 6 months | Mesenchymal stem cells |
Pain relief | 12 months | Mesenchymal stem cells |
Functional improvement | 12 months | Mesenchymal stem cells |
For a patient who has already tried HA injections without satisfactory or lasting relief, this evidence suggests that MSC therapy represents a meaningful step forward. Importantly, both pain relief and physical function improved—meaning the benefit is not simply about feeling less pain, but about being able to move and live more comfortably. Patients interested in understanding stem cell therapy for knee conditions more broadly will find that the knee is one of the most studied and well-supported areas in orthopedic regenerative medicine.
While the evidence is encouraging, patients should approach stem cell therapy with accurate expectations and a well-informed mindset.
The source, preparation, and concentration of MSCs can vary significantly between providers and products. Bone marrow-derived, adipose-derived, and umbilical cord-derived MSC preparations each have different characteristics. Patients should ask their provider about the source and quality of the cells being used. For a detailed comparison, R3’s guide on bone marrow stem cells vs. adipose fat stem cells outlines the key safety and efficacy distinctions.
In the United States, the FDA regulates stem cell therapies. Understanding the relationship between stem cells and the FDA is important for any patient evaluating a provider. Clinics offering MSC injections operate under specific regulatory frameworks, and patients should ensure any provider they consult is operating within appropriate legal and medical standards. R3 Stem Cell has published a detailed overview of FDA regulations on human cell and tissue-based products, covering the 351 vs. 361 classification distinction that governs this space.
Stem cell therapy is generally not covered by insurance and is considered an out-of-pocket expense. The cost varies by provider, treatment protocol, and geography. R3 Stem Cell provides transparent pricing information for those researching the cost of stem cell therapy to help patients plan appropriately.
MSC therapy is not appropriate for every patient. Generally, better candidates tend to be those with:
Mild to moderate knee osteoarthritis
Ongoing pain despite conservative treatments including HA injections, physical therapy, or NSAIDs
A desire to avoid or delay total knee replacement
No active joint infection or certain other contraindications
The most reliable way to assess candidacy is through a thorough consultation. Learning how to choose the right stem cell clinic and how to choose your stem cell therapy physician are essential steps before committing to any provider.
R3 Stem Cell is a regenerative medicine provider with deep expertise in mesenchymal stem cell therapy for musculoskeletal conditions including knee osteoarthritis. The practice offers free consultations for prospective patients to assess whether stem cell therapy is appropriate for their individual situation—an important first step before committing to any treatment.
Patients can also learn what to expect from stem cell therapy and how the body reacts to stem cell injections to feel more informed and confident going into the process. R3’s stem cell therapy FAQ is another excellent resource for patients with specific questions about procedure, recovery, and outcomes.
As with any medical decision, the consultation process should include a full review of your imaging (X-rays, MRI), treatment history, and health status to determine the most appropriate course of action.
The comparison between mesenchymal stem cell injections and hyaluronic acid injections for knee arthritis is no longer purely theoretical. A well-structured meta-analysis drawing on data from hundreds of patients demonstrates a measurable and sustained advantage for stem cell therapy at both six months and one year following treatment.
For patients who have reached the limits of what HA injections can offer, MSC therapy represents a scientifically supported, non-surgical option worth discussing with a qualified regenerative medicine specialist. To take the next step, explore R3 Stem Cell’s full guide on stem cell therapy for arthritis or review the benefits of stem cell therapy across the full range of musculoskeletal conditions they treat.
Contact Us
Consent alone is not sufficient. Donor mothers also undergo comprehensive medical screening, which typically includes: